Explore

Trendline Trendline
Eli Lilly Showcases Weight Loss Drug Benefits at American Diabetes Association Meeting

Eli Lilly Showcases Weight Loss Drug Benefits at American Diabetes Association Meeting

Eli Lilly Showcases Weight Loss Drug Benefits at American Diabetes Association Meeting
Trendline Trendline
OrsoBio to Present New Data on Mitochondrial Protonophore at ADA 2026, Highlighting Potential Benefits for Obesity Treatment

OrsoBio to Present New Data on Mitochondrial Protonophore at ADA 2026, Highlighting Potential Benefits for Obesity Treatment

OrsoBio to Present New Data on Mitochondrial Protonophore at ADA 2026, Highlighting Potential Benefits for Obesity Treatment
Trendline Trendline
Eli Lilly's Retatrutide Shows Promising Weight Loss Results in Obesity Treatment

Eli Lilly's Retatrutide Shows Promising Weight Loss Results in Obesity Treatment

Eli Lilly's Retatrutide Shows Promising Weight Loss Results in Obesity Treatment
Trendline Trendline
Eli Lilly Unveils Promising Obesity Therapy Results at ADA Conference

Eli Lilly Unveils Promising Obesity Therapy Results at ADA Conference

Eli Lilly Unveils Promising Obesity Therapy Results at ADA Conference
Trendline Trendline
Roche and Zealand Pharma's Amylin Analog Petrelintide Shows Moderate Weight Loss in Phase 2 Study

Roche and Zealand Pharma's Amylin Analog Petrelintide Shows Moderate Weight Loss in Phase 2 Study

Roche and Zealand Pharma's Amylin Analog Petrelintide Shows Moderate Weight Loss in Phase 2 Study
Reuters Reuters
S&P 500, Nasdaq futures climb as chip stocks stabilize

S&P 500, Nasdaq futures climb as chip stocks stabilize

June 8 (Reuters) - S&P 500 and Nasdaq futures climbed on Monday, as chip stocks steadied after plunging to over two-week lows, though renewed strikes in the Middle East kept investors largely at bay.
Trendline Trendline
Boehringer Ingelheim's Survodutide Shows Efficacy in Obesity Trials but Faces Safety Concerns

Boehringer Ingelheim's Survodutide Shows Efficacy in Obesity Trials but Faces Safety Concerns

Boehringer Ingelheim's Survodutide Shows Efficacy in Obesity Trials but Faces Safety Concerns
TheStreet TheStreet
Eli Lilly makes surprising retreat from major market

Eli Lilly makes surprising retreat from major market

Eli Lilly's (LLY) chairman and CEO Dave Ricks told German business newspaper Handelsblatt that Lilly would halve its planned investment in Germany, cutting its original 2.3 billion euro ($2.67 billion) commitment by roughly 50%. Reuters reported the announcement on June 3, 2026. The pullback lands ...
Trendline Trendline
OrsoBio to Present New Data on Mitochondrial Protonophore at ADA 2026

OrsoBio to Present New Data on Mitochondrial Protonophore at ADA 2026

OrsoBio to Present New Data on Mitochondrial Protonophore at ADA 2026
Reuters Reuters
Factbox-Major brokerages' forecasts for S&P 500, global GDP growth in 2026

Factbox-Major brokerages' forecasts for S&P 500, global GDP growth in 2026

June 8 (Reuters) - Top brokerages expect the benchmark S&P 500 index to extend its rally in 2026, even as the months-long Middle East conflict disrupts global energy flows and drives inflation higher.
Trendline Trendline
Novo Nordisk CEO Confident in CagriSema's Market Impact Amid Obesity Drug Competition

Novo Nordisk CEO Confident in CagriSema's Market Impact Amid Obesity Drug Competition

Novo Nordisk CEO Confident in CagriSema's Market Impact Amid Obesity Drug Competition
Trendline Trendline
Eli Lilly and Novo Nordisk Compete at ADA 2026 Amid Rising Obesity Drug Market

Eli Lilly and Novo Nordisk Compete at ADA 2026 Amid Rising Obesity Drug Market

Eli Lilly and Novo Nordisk Compete at ADA 2026 Amid Rising Obesity Drug Market